A carregar...
Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial
BACKGROUND: Bevacizumab is a recombinant humanized monoclonal immunoglobulin G1 antibody targeting VEGF-A. It is currently used with chemotherapy as the first- or second-line therapy in metastatic colorectal cancer. Previous studies have showed that anti-angiogenic agents decrease capillary density....
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5849157/ https://ncbi.nlm.nih.gov/pubmed/29560093 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22822 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|